Stathmin is a Marker of Progression and Poor Prognosis in Esophageal Carcinoma

  • Wang, Feng (Department of Oncology, the First Affiliated Hospital of Zhengzhou University) ;
  • Xuan, Xiao-Yan (Department of Microbiology and Immunology, Zhengzhou University) ;
  • Yang, Xuan (Department of Microbiology and Immunology, Zhengzhou University) ;
  • Cao, Lei (Department of Oncology, the First Affiliated Hospital of Zhengzhou University) ;
  • Pang, Li-Na (Department of Oncology, the First Affiliated Hospital of Zhengzhou University) ;
  • Zhou, Ran (Department of Oncology, the First Affiliated Hospital of Zhengzhou University) ;
  • Fan, Qin-Xia (Department of Oncology, the First Affiliated Hospital of Zhengzhou University) ;
  • Wang, Liu-Xing (Department of Oncology, the First Affiliated Hospital of Zhengzhou University)
  • Published : 2014.04.30


Stathmin, also called oncoprotein 18, is a founding member of the family of microtubule-destabilizing proteins that play a critical role in the regulation of mitosis. At the same time stathmin has been recognized as one of responsible factors in cancer cells. The aim of this study was to assess stathmin status, its correlations with clinicopathological parameters and its role as a progosnostic marker in EC patients. The protein and mRNA levels of stathmin were examined byimmunohistochemistry (IHC) and in situ hybridization in 100EC tissues and adjacent noncancerous tissues. mRNA and protein expression of stathmin in three EC cell lines(EC9706, ECa109, EC1 commonly used in research) were also analyzed using immunocytochemistry, western blot and in situ hybridization. The prognostic value of Stathmin expression within the tumor tissues were assessed by Cox regression and Kaplan-Meier analysis. We showed that stathmin expression was significantly higher in EC tissues than in adjacent noncancerous tissues. High stathmin immunostaining score in the EC was positively correlated with tumor differentiation, Tumor invasion, Lymph node metastases, and TNM stage. In addition, we demonstrated that three EC cell lines examined, were constitutively expressing a high level of stathmin. Of those, EC-1 showed the strongest mRNA and protein expression for the stathmin analyzed. Kaplan-Meier analysis showed that significantly longer 5-year survival rate was seen in EC patients with high Stathmin expression, compared to those with low expression of Stathmin expression. Furthermore, multivariate Cox proportional hazard analyses revealed that Stathmin was an independent factors affecting the overall survival probability. In conclusion, our data provide a basis for the concept that stathmin might be associated with EC development and progression. High levels of Stathmin expression in the tumor tissues may be a good prognostic marker for patients with EC.


  1. D’Andrea S, Berton S, Segatto I, et al (2012). Stathmin is dispensable for tumor onset in mice. PLoS One, 7, 45561.
  2. Han ZX, Wang HM, Jiang G, et al (2013). Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2. Cancer Biother Radiopharm, 28, 398-405.
  3. He W, Li K, Wang F, Qin YR, Fan QX (2012). Expression of OCT4 in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. World J Gastroenterol, 18, 712-9.
  4. Holmfeldt P, Larsson N, Segerman B, et al (2001). The Catastrophe-promoting Activity of Ectopic Op18/Stathmin Is Required for Disruption of Mitotic Spindles But Not Interphase Microtubules. Mol Biol Cell, 12, 73-83.
  5. Hou X, Wei JC, Wu JX et al (2013). Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PLoS One, 8, 69259.
  6. Iancu-Rubin C, Gajzer D, Tripodi J, et al (2011). Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood, 117, 4580-9.
  7. Jeon TY, Han ME, Lee YW, et al (2010). Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer, 102, 710-18.
  8. Karst AM, Levanon K, Duraisamy S, et al (2011). Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol, 123, 5-12.
  9. Kouzu Y, Uzawa K, Koike H, et al (2006). Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer, 94, 717-23.
  10. Li N, Jiang P, Du W, et al (2011). Siva1 suppresses epithelial–mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci USA, 108, 12851-6.
  11. Liu F, Sun YL, Xu Y, et al (2013). Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma. Oncol Rep, 29, 419-24.
  12. Miceli C, Tejada A, Castaneda A, Mistry SJ (2013). Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Cancer Gene Ther, 20, 298-307.
  13. Qi B, Yao WJ, Zhao BS, et al (2013), Involvement of microRNA-198 overexpression in the poor prognosis of esophageal cancer. Asian Pac J Cancer Prev, 14, 5073-6.
  14. Song PI, Liang H, Fan JH, et al (2011). Long-term survival after esophagectomy for early esophageal squamous cell carcinoma in Linxian, China. J Surg Oncol, 104, 176-80.
  15. Tian X, Tian Y, Sarich N, Wu T, Birukova AA (2013). Novel role of stathmin in microtubule-dependent control of endothelial permeability. FASEB J, 26, 3862-74.
  16. Tsvetkov PO, Barbier P, Breuzard G, Peyrot V, Devred F (2013). Microtubule- associated proteins and tubulin interaction by isothermal titration calorimetry. Methods Cell Biol, 115, 283-302.
  17. Wang Q, Ma C, Kemmner W (2013). Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cellcarcinoma. BMC Cancer, 13, 137.
  18. Wang R, Dong K, Lin F, et al (2007). Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med, 13, 567-75.
  19. Werner HM, Trovik J, Halle MK, et al (2014). Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One, 9, 90141.
  20. Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, et al (2011). Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol, 186, 2094-100.
  21. Wu IC, Wu CC, Lu CY, et al (2013). Substance use (Alcohol, Areca Nut and Cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One, 8, 55834.
  22. Ying L, Su D, Zhu J, et al (2013). Genotyping of stathmin and its association with clinical factors and survival in patients with ovariancancer. Oncol Lett, 5, 1315-20.
  23. Yoon MS, Nam TK, Lee JS, et al (2011). VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. Korean Med Sci, 26, 513-20.
  24. Yuan SF, Chen WJ, Zhu LJ, et al (2013). Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56human lung carcinoma cell line. Asian Pac J Cancer Prev, 13, 2967-71.
  25. Yuen HF, McCrudden CM, Chan KK, et al (2011). The Role of pea3 group transcription factors in esophageal squamous cell carcinoma. Am J Pathol, 179, 992-1003.

Cited by

  1. Stathmin 1, a Therapeutic Target in Esophageal Carcinoma? vol.15, pp.15, 2014,
  2. Anti-centrosome antibodies in breast cancer are the expression of autoimmunity vol.60, pp.2-3, 2014,
  3. Roles of human papillomavirus infection and stathmin in the pathogenesis of sinonasal inverted papilloma vol.38, pp.2, 2015,
  4. Proteomic Signatures of Thymomas vol.11, pp.11, 2016,
  5. Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments vol.14, pp.1, 2016,
  6. High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens vol.17, pp.1, 2017,
  7. Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity through inhibition of autophagy vol.13, pp.5, 2017,
  8. Possible biomarkers for predicting lymph node metastasis of esophageal squamous cell carcinoma: a review vol.47, pp.2, 2019,